随着生物制剂工厂生产规模的扩大，Eris生命科学有限公司（Eris Lifesciences Ltd.）预计2026-27财年下半年的利润率将进一步改善，该公司预测毛利率将扩大150至200个基点。
Eris Lifesciences Ltd. expects margins to improve further in the second half of the financial year 2026-27 as production from its biologics facilities ramps up, with the company guiding for a 150-200 basis point expansion in gross margins.
在此展望出台之前，这家制药公司报告称，其第二季度营收增长了13%，而息税折旧摊销前利润率（EBITDA margins）保持在34%以上。董事长兼董事总经理阿米特·巴克希（Amit Bakshi）表示，预计公司的生物制剂投资和收购业务的扭亏为盈将在未来几个季度支撑盈利能力。
The outlook comes after the pharmaceutical company reported a 13% increase in second-quarter revenue, while earnings before interest, taxes, depreciation, and amortisation margins remained above 34%. Chairman and Managing Director Amit Bakshi said the company's biologics investments and turnaround in acquired businesses are expected to support profitability over the coming quarters.
他补充说，到27财年，国内品牌配方药预计将带来36-37%的EBITDA利润率，而合并利润率应保持在35%左右。
He added that domestic branded formulations are expected to deliver 36-37% EBITDA margins, while consolidated margins should remain around 35% by FY27.
巴克希表示，Eris已显著提高了收购业务的盈利能力。一个EBITDA利润率在10%左右的皮肤科收购项目以及利润率为15-16%的百奥康（Biocon）产品组合，现在已经接近该公司国内品牌配方药约36%的利润率。
该公司认为，加强生物制剂的内部制造（尤其是糖尿病疗法）将继续提高毛利率。
Bakshi said Eris has significantly improved the profitability of acquired businesses. One dermatology acquisition that operated at around 10% EBITDA margins and the Biocon portfolio, which was at 15-16%, have now moved closer to the company's domestic branded formulations margin of around 36%.The company believes greater in-house manufacturing of biologics, particularly diabetes therapies, will continue to improve gross margins.
在糖尿病药物司美格鲁肽（semaglutide）方面，巴克希表示，Eris在处方量和销量方面继续领跑市场。
On diabetes drug semaglutide, Bakshi said Eris continues to lead the market in prescriptions and unit sales.
他表示，由于推出了旨在提高患者用药可及性的西林瓶装产品，该公司按价值计算排名第二。截至中午12点24分，Eris生命科学公司的股票在国家证券交易所（NSE）的交易价格为1,178.10卢比。该股在过去一年中下跌了27%以上，使该公司的市值达到163.5936亿卢比。
He said that the company ranks second by value because of its vial-based offering aimed at improving patient access. Eris Lifesciences shares were trading at ₹1,178.10 on the NSE at 12:24 pm. The stock has declined more than 27% over the past year, giving the company a market capitalisation of ₹16,359.36 crore.
巴克希预计，随着医生接受度的提高，印度的GLP-1市场将进一步扩大。
Bakshi expects India's GLP-1 market to expand further as physician adoption increases.
他补充说，医生目前正处于处方该疗法的体验阶段，随后将在未来六到九个月内实现更广泛的采用。
He added that doctors are currently in the experience phase of prescribing the therapy before broader adoption takes place over the next six to nine months.
在出口业务方面，巴克希重申，由于该公司在完成与GMP相关的观察结果后的整改工作，近期国际营收可能保持持平或实现低个位数增长。出口额占Eris营收的不到10%。
On the exports business, Bakshi reiterated that international revenue is likely to remain flat to low single-digit growth in the near term as the company completes remediation following GMP-related observations. Exports contribute less than 10% of Eris' revenue.
他表示，一个新的生产区块预计将在3月至4月进入工艺验证批次。一旦该设施获得监管批准并且GMP问题得到解决，预计明年出口将大幅改善。
He said a new manufacturing block is expected to enter process validation batches by March-April. Once the facility receives regulatory approvals and the GMP issue is resolved, exports are expected to improve meaningfully next year.
尽管存在出口逆风，但在国内业务的支持下，Eris预计整体营收增长将维持在约13%的当前水平附近。
Despite the export headwinds, Eris expects overall revenue growth to remain around the current level of approximately 13%, supported by its domestic business.
巴克希还概述了公司的去杠杆计划。在过去几年对生物制剂制造进行了大量投资之后，随着设施进入监管审批阶段，Eris预计资本支出将放缓。
Bakshi also outlined the company's deleveraging plans. After investing heavily in biologics manufacturing over the past few years, Eris expects capital expenditure to moderate as facilities move into the regulatory approval phase.
该公司预计在下半年再削减150至200亿卢比的债务，并计划在下一个财年进行更大规模的削减。完整采访内容，
The company expects to reduce debt by another ₹150-200 crore during the second half, with a sharper reduction planned in the next financial year. For the full interview,